Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyTOF Analysis of PBMC in AD and DLB
NCT05518409Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of donepezil in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Immunerepertorie at 1 year and immunological Elastic-Net (iEN) model at 1 year. Status: unknown.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT05518409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518409.